Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Immunol.

Sec. Autoimmune and Autoinflammatory Disorders: Autoinflammatory Disorders

This article is part of the Research TopicCommunity series: hunting for inflammation mediators: identifying novel biomarkers for autoimmune and autoinflammatory diseases- volume IIView all 7 articles

Amelioration of Psoriasis-Like Skin Lesions by Human Amniotic Mesenchymal Stem Cells: Insights from Multiomics Profiling in Mice

Provisionally accepted
  • 1China-Japan Union Hospital of Jilin University Department of Dermatology, Changchun, China
  • 2China-Japan Union Hospital, Jilin University, Changchun, China
  • 3China-Japan Union Hospital of Jilin University, Changchun, China
  • 4Changchun Sci-Tech University, Changchun, China
  • 5Jilin University, Changchun, China

The final, formatted version of the article will be published soon.

Background Psoriasis is a multifactorial, chronic inflammatory skin disease. Current treatment modalities are limited by suboptimal patient responses and high recurrence rates after discontinuation. Consequently, there is an urgent need to develop novel therapeutic strategies for psoriasis. Methods An imiquimod‐induced mouse model of psoriasis was established, and human amniotic mesenchymal stem cell (hAMSC) were subsequently administered to evaluate their therapeutic efficacy. Bioinformatic analyses of Gene Expression Omnibus (GEO) datasets GSE39035 and GSE97311 were performed to identify potential hAMSC therapeutic target genes. Using data from GSE228421, a single-cell transcriptomic atlas of psoriasis was constructed to examine the distribution and functional roles of these target genes across different cell populations. Results By integrating an imiquimod-induced murine model with comprehensive bioinformatic analyses of GEO datasets, we demonstrated that hAMSC administration significantly ameliorated psoriasis-like skin lesions, restored epidermal architecture, and reduced PASI and Baker scores. This therapeutic efficacy was accompanied by the alleviation of splenomegaly and a systemic reduction in inflammatory cytokines (IL-17 and TNF-α) without inducing hepatotoxicity. In vitro experiments further confirmed that hAMSCs inhibited TNF-α-induced keratinocyte proliferation and reactive oxygen species (ROS) generation. Transcriptomic profiling identified key immune-related targets, revealing that hAMSCs significantly modulated the expression of genes such as MMP9, S100A9, and BACH2. It is worth noting that single-cell atlas analysis has revealed that S100A9 and MMP9 play significant roles respectively in psoriasis-related CD8-IL17A T cells and M2-like macrophages, and further clarified the functional characteristics of S100A9 in the temporal development process of psoriasis fibroblasts and keratinocytes. Conclusions In summary, our findings confirm the efficacy and safety of hAMSCs in the treatment of psoriasis and elucidate the underlying mechanisms of their therapeutic action.

Keywords: human amniotic mesenchymal stem cell, MMP9, Psoriasis, S100A9, single cell

Received: 28 Dec 2025; Accepted: 30 Jan 2026.

Copyright: © 2026 Yang, Miao, Sun, Zhang, Sun, Zhou, Hu, Cui, Wang, Liu, Zhang, Hu and Cong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Qianying Hu
Xianling Cong

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.